A group of drugs used to treat anemia in cancer patients undergoing chemotherapy has again been linked to a greater risk of blood clots and death, this time by a study published in the Journal of the American Medical Association.
Boston Scientific Corp.'s annual report to the U.S. Securities and Exchange Commission said Thursday that the Department of Justice is investigating allegations that the company promoted its biliary stents for off-label uses.
A federal jury on Tuesday ordered supplement tycoon Steve Warshak and his company to forfeit $33 million in cash and assets derived in part from sales of the Enzyte "male enhancement" product advertised on late-night television.
With many senior government officials looking to the future as the Bush administration winds down, U.S Federal Trade Commission Chairman Deborah Platt Majoras revealed Thursday she will be resigning from the agency in late March.
Finding all of Church & Dwight Co.'s asserted pregnancy test patents valid, a federal jury awarded the company damages of $14.6 million in a patent battle with Abbott Laboratories Inc.
A federal appeals court panel issued a mixed ruling Thursday in a patent infringement suit that the University of California and Abbott filed against Danish cancer diagnostics firm Dako A/S, finding that the lower court correctly construed some, but not all, claims in the case.
A Dutch court has invalidated a patent for Pfizer Inc.'s Lipitor, but generics drugmaker Ranbaxy Laboratories Inc. is still blocked from launching a generic version of the blockbuster cholesterol drug.
In a whistleblower case over Pfizer Inc.’s alleged illegal marketing of human growth hormone Genotropin, a judge has denied Pfizer Inc.’s bid to force a former executive to turn over information as to whether he made adequate efforts to look for work after he was fired.
The U.S. Food and Drug Administration posted a public health notification on its Web site Monday in response to 72 reports of sickness and one fatality related to the use of denture cleaners.
Entering the bullpen once again, India is taking up the issue of how to balance patent protection with patient need, with the country's patent office reportedly set to consider this week whether to override patents on cancer drugs made by Pfizer Inc. and Roche AG and to allow a generics maker to ship copycat versions to Nepal for distribution.
Concerned over reports of impropriety, a prominent Republican senator is reportedly demanding answers from the U.S. Food and Drug Administration and the maker of Prodisc over rumors that some doctors involved in the clinical research of the synthetic spinal disk stood to gain financially from the medication's success.
A California federal court has allowed Foley & Lardner LLP to add new defenses against a pharmaceutical development company that claims it lost international rights to drug delivery technology because the law firm filed a patent application late.
Four years after joining a global system for recognizing trademarks, the United States ranks third among countries with the most international trademark applications, trailing Germany and France, according to a report from the United Nations trademark agency.
DLA Piper is continuing to work toward establishing itself as a leader in the global life sciences marketplace, most recently by hiring experienced corporate attorney Bruce W. Jenett, former co-chair of the life sciences practice at Heller Ehrman LLP.
A federal judge has, for the second time, decided to reconsider a December claims construction order in Medtronic Inc.’s infringement suit against Abbott Laboratories and its cardiovascular unit over balloon catheter and stent patents.
U.S. lawmakers have called for legislation mandating full disclosure of health care industry payments to physicians, following revelations that five top orthopedic implant makers spent $230 million on payments to doctors last year.
In the wake of a rash of recent drug recalls, the U.S. Food and Drug Administration reportedly is set to keep a closer eye on the use of medicines after they have reached the market, marking a shift from its traditional focus on pre-approval monitoring of new treatments.
Our daily calendar of events lists conferences and hearings scheduled to take place in the next four weeks.
Apotex Corp. and Pfizer Inc. have settled all outstanding patent infringement and antitrust litigation over Pfizer's blockbuster epilepsy drug, Neurontin, which had earned the company more than $2 billion a year.
Marking a sweeping victory for AstraZeneca, a federal judge ruled Monday that a group of drugstores had failed to prove the pharmaceutical giant violated antitrust law when it put its marketing muscle behind heartburn drug Nexium instead of Prilosec as the latter's patent protection was about to lapse.